ORGANIZATION

• Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
  June 18, 2018

• FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
  June 18, 2018

• Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee
  June 18, 2018

• Hiroki Nakatani Named as New Board Chair for GHIT Fund
  June 8, 2018

• JPMA Proposes Creation of Disease Registry to Employ Medical Data
  June 5, 2018

• New JPMA Chief Calls for Scrapping PMP Company Criteria
  June 1, 2018

• Sawai President Elected New Generic Industry Chief
  May 30, 2018

• Drug Damage Watchdog Submits Opinion to Health Ministry, Opposing Current Conditional Early Approval System
  May 30, 2018

• Big Data Analysis Finds Low Generic Drug Use Rate among Healthcare Professionals: Kyokai Kenpo
  May 28, 2018

• Daiichi Sankyo CEO Nakayama Appointed as New President of JPMA
  May 25, 2018

• Isao Teshirogi Elected New FPMAJ Chairman
  May 25, 2018

• PhRMA Vision Report Stresses Innovation as Investment for Healthier Lifespans
  May 17, 2018

• Over 80% Concerned about Restrictions on Access to Prescription Drugs: PhRMA Survey
  May 15, 2018

• Drug Damage Watchdog Calls for 3rd Party Long-Term Investigation for HPV
  May 2, 2018

• PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
  April 26, 2018

• PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
  April 26, 2018

• No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says
  April 20, 2018

• Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
  April 16, 2018

• PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
  April 13, 2018

• Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
  April 9, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 37
• 38
• 39
• 40
• 41
• 42
• 43
• 44
• 45
• …
• Next ›
• 最終 »